ATE375168T1 - Die synergistischen wirkungen von hgf und antibakterieller behandlung - Google Patents

Die synergistischen wirkungen von hgf und antibakterieller behandlung

Info

Publication number
ATE375168T1
ATE375168T1 AT01963646T AT01963646T ATE375168T1 AT E375168 T1 ATE375168 T1 AT E375168T1 AT 01963646 T AT01963646 T AT 01963646T AT 01963646 T AT01963646 T AT 01963646T AT E375168 T1 ATE375168 T1 AT E375168T1
Authority
AT
Austria
Prior art keywords
hgf
synergistic effects
antibacterial treatment
ongoing
septicaemia
Prior art date
Application number
AT01963646T
Other languages
English (en)
Inventor
Fariba Nayeri
Original Assignee
Damavand Wound Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0003038A external-priority patent/SE0003038L/xx
Priority claimed from SE0101823A external-priority patent/SE0101823D0/xx
Application filed by Damavand Wound Ab filed Critical Damavand Wound Ab
Application granted granted Critical
Publication of ATE375168T1 publication Critical patent/ATE375168T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01963646T 2000-08-28 2001-08-28 Die synergistischen wirkungen von hgf und antibakterieller behandlung ATE375168T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0003038A SE0003038L (sv) 2000-08-28 2000-08-28 Synergieffekter av HGF och antibakteriell behandling
SE0101823A SE0101823D0 (sv) 2001-05-21 2001-05-21 Analysis of excrement with regard to hepatocyte growth factor

Publications (1)

Publication Number Publication Date
ATE375168T1 true ATE375168T1 (de) 2007-10-15

Family

ID=26655219

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01963646T ATE375168T1 (de) 2000-08-28 2001-08-28 Die synergistischen wirkungen von hgf und antibakterieller behandlung

Country Status (7)

Country Link
US (2) US7601365B2 (de)
EP (3) EP1320384B1 (de)
AT (1) ATE375168T1 (de)
AU (1) AU2001284576A1 (de)
DE (1) DE60130906T2 (de)
ES (1) ES2295198T3 (de)
WO (1) WO2002017964A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037365A1 (en) * 2001-11-01 2003-05-08 The Johns Hopkins University Methods and compositions for treating vascular leak using hepatocyte growth factor
JP4728807B2 (ja) * 2003-09-03 2011-07-20 敏一 中村 ヒト組換えｈｇｆを含有する皮膚潰瘍予防治癒剤
DK1687636T3 (da) * 2003-09-29 2009-05-11 Peas Inst Ab Hurtig bestemmelse af forskellige former for hepatocytvækstfaktor (HGF) i legemsvæsker
US20080261233A1 (en) 2004-10-20 2008-10-23 Peas Institut Ab Assessment of Biological Activity of Hepatocyte Growth Factor (Hgf)
ATE541584T1 (de) * 2005-11-16 2012-02-15 Fariba Nayeri Verfahren zur hemmung von krebsbildung und/oder metastasen bei einer person durch endogene c-met- liganden und -hemmer
WO2011028173A1 (en) * 2009-09-05 2011-03-10 Fariba Nayeri Method of treatment of a patient suffering from an infection or injuries caused or complicated by infection
SE536400C2 (sv) 2012-02-22 2013-10-08 Peas Inst Ab Ny metod för snabb detektion av hepatocyttillväxtfaktor i biologiska vätskor
RU2597781C1 (ru) * 2015-05-21 2016-09-20 федеральное государственное бюджетное образовательное учреждение высшего образования "Тверской государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ дифференциальной диагностики сальмонеллёзного гастроэнтерита и алкогольного гастроэнтерита
RU2597780C1 (ru) * 2015-05-21 2016-09-20 федеральное государственное бюджетное образовательное учреждение высшего образования "Тверской государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ дифференциальной диагностики сальмонеллёзного гастроэнтерита и алкогольного гастроэнтерита
RU2716713C1 (ru) * 2019-08-01 2020-03-16 Федеральное государственное бюджетное учреждение науки Оренбургский федеральный исследовательский центр Уральского отделения Российской академии наук Способ диагностики стадии острого пиелонефрита

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US176347A (en) * 1876-04-18 Improvement in filling packages with comb-honey
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
US5648273A (en) 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
JP2750372B2 (ja) 1990-06-19 1998-05-13 敏一 中村 賢疾患治療剤
JP3200609B2 (ja) * 1990-12-28 2001-08-20 敏一 中村 上皮細胞増殖促進剤
JPH083195A (ja) 1991-10-04 1996-01-09 Toshiichi Nakamura 組織傷害治癒因子
JP3394982B2 (ja) 1991-11-07 2003-04-07 敏一 中村 ガン療法用副作用防止剤
WO1994004175A1 (en) 1992-08-24 1994-03-03 Toshikazu Nakamura Hgf production promoter
JP3680114B2 (ja) 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
JP3962097B2 (ja) * 1994-03-18 2007-08-22 敏一 中村 免疫抑制剤による副作用の軽減剤
JP3818322B2 (ja) * 1994-04-28 2006-09-06 敏一 中村 コラーゲン分解促進剤
JP3477832B2 (ja) * 1994-07-22 2003-12-10 三菱化学株式会社 肝疾患の検出方法
US5656443A (en) * 1994-07-29 1997-08-12 Long Island Jewish Medical Center Method of diagnosing bladder cancer
US6756358B2 (en) * 1994-08-19 2004-06-29 Sumitomo Pharmaceuticals Co., Ltd. Therapeutic agent for cartilaginous diseases
JP3737532B2 (ja) 1994-08-19 2006-01-18 敏一 中村 軟骨障害治療剤
EP0816381B1 (de) * 1995-03-10 2004-01-14 NAKAMURA, Toshikazu Menschlicher wachstumsfaktor (hgf), verändert durch polyethylenglykol
JPH08268907A (ja) * 1995-03-31 1996-10-15 Sunstar Inc 歯周組織再生促進剤
EP0830381A4 (de) * 1995-06-09 2000-11-22 William N Drohan Chitinhydrogele, herstellungsverfahren und anwendung
DE69634567T2 (de) 1995-08-29 2006-02-16 Anges Mg Inc., Toyonaka Ein medikament,das hgf gen enthält
JPH11512435A (ja) * 1995-09-12 1999-10-26 ジェネンテック インコーポレーテッド 嚢胞性繊維症の治療
JP3832674B2 (ja) 1995-10-24 2006-10-11 敏一 中村 抗癌剤
US5827673A (en) * 1996-08-13 1998-10-27 Akira Matsumori Method of detecting myocardial infarction
JP4463885B2 (ja) 1996-12-05 2010-05-19 敏一 中村 劇症肝炎疾患治療剤
DE69832165T2 (de) 1997-03-15 2006-04-20 Nakamura, Toshikazu Hgf zur behandlung von akutem nierenversagen
CA2218145C (en) * 1997-04-14 2008-01-08 Toshikazu Nakamura Method of treating dilated cardiomyopathy
WO1999055361A1 (fr) 1998-04-28 1999-11-04 Toshikazu Nakamura Inhibiteurs de neovascularisation
EP1242451A2 (de) * 1999-12-15 2002-09-25 EntreMed, Inc. Zusammensetzung und verfahren zur hemmung der proliferation von endothelzellen
US20030176347A1 (en) 2003-05-14 2003-09-18 Toshikazu Nakamura Remedies for amyotrophic lateral sclerosis
JP5442173B2 (ja) 2000-09-14 2014-03-12 敏一 中村 筋萎縮性側索硬化症治療剤

Also Published As

Publication number Publication date
ES2295198T3 (es) 2008-04-16
EP1840575A1 (de) 2007-10-03
WO2002017964A1 (en) 2002-03-07
US7601365B2 (en) 2009-10-13
AU2001284576A1 (en) 2002-03-13
EP1320384A1 (de) 2003-06-25
DE60130906D1 (de) 2007-11-22
DE60130906T2 (de) 2008-07-17
EP1320384B1 (de) 2007-10-10
US20040042968A1 (en) 2004-03-04
US20100160223A1 (en) 2010-06-24
EP1867996A1 (de) 2007-12-19

Similar Documents

Publication Publication Date Title
DE60119939D1 (de) Chinolinderivate als antibakterielle mittel
DK1284740T3 (da) Profylaktisk og terapeutisk behandling af infektiöse sygdomme, autoimmunsygdomme og allergiske sygdomme med monosaccharidbaserede forbindelser
DE68917163T2 (de) Antibakterielle Mittel.
DE60123276D1 (de) Piperazinderivate zur behandlung bakterieller infektionen
ATE326525T1 (de) Bifidobakterium zur behandlung von entzündungskrankheiten
MA25775A1 (fr) Combinaison des bacteries d'acide lactique et son utilisation pour la prevention et/ou le traitement des infections et des etats inflammatoires.
EA200400536A1 (ru) Макролиды
HUP0400719A2 (hu) Vegyületek és eljárások Chlamydia-fertőzés diagnosztikájára és kezelésére
ATE344799T1 (de) Piperidinderivate als antibakterielle mittel
ATE305793T1 (de) Bakteriophage mit breitem wirtspektrum
TNSN03121A1 (en) Formes cristallines d'azithromycine
CY2011012I1 (el) Εισπνευσιμη αζτρεοναμη για τη θεραπεια και την προληψη πνευμονικων βακτηριακων λοιμωξεων
TR200400072T4 (tr) Novel Biarylcarboxamides Biarylcarboxamide Nouveaux Biarylcarboxamides
ATE346046T1 (de) Chinoline und deren in der 4-stellung durch eine piperazinhaltige gruppe substituierte nitrogenierte derivate und deren verwendung als antibakterielle mittel
DE69636228D1 (de) Therapeutische Zusammensetzungen zur Behandlung von Lawsonia intracellularis Infektionen
DE60237725D1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
PT1322648E (pt) Derivados de acidos 3-(heteroarilacetamido)-2-oxo-azetidina-1-sulfonicos como agentes antibacterianos
ATE375168T1 (de) Die synergistischen wirkungen von hgf und antibakterieller behandlung
ATE335499T1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
ES2191075T3 (es) 8-arilalquil- y 8-arilheteroalquil-5,11-dihidro-6h-dipirido-(3,2-b:2',3'-e)(1,4)diazepinas y su uso en la prevencion o tratamiento de infecciones por hiv.
MA28613B1 (fr) Macrocycles d'amide antibacteriens
DE60142958D1 (de) Verwendung von retinoid-typ verbindungen als antibakterielle mittel gegen staphylococcus aureus
ITMI20011876A0 (it) Apparecchiatura per l'accelerazione del trattamento dei capelli
DE60112581D1 (de) Zusammensetzungen zur behandlung baktrieller infektionen, welche ein oxazolidinonderivat, sulbactam und ampicillin enthalten
DE60125212D1 (de) Verwendung von Aivlosin zur Behandlung und Prevention der Lawsonia-Infektionen in Schweinen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1320384

Country of ref document: EP